Diverse, Inclusive Clinical Research Begins with Optimized Trial Design

Diversity in clinical research has become a hot topic in recent years, with heightened attention leading to dramatic changes in the regulatory framework. The U.S. Food and Drug Administration Omnibus Reform Act of 2022 (FDORA) is one of the most notable. Now, just over a year since FDORA’s implementation, the industry’s perspective on diversity has undoubtedly evolved.